Show simple item record

dc.contributor.authorHakkarainen, Katja Marja
dc.contributor.authorJuuti, Rosa
dc.contributor.authorBurkill, Sarah
dc.contributor.authorGeissbühler, Yvonne
dc.contributor.authorSabidó, Meritxell
dc.contributor.authorPopescu, Catrinel
dc.contributor.authorSuzart-Woischnik, Kiliana
dc.contributor.authorHillert, Jan
dc.contributor.authorArtama, Miia
dc.contributor.authorVerkkoniemi-Ahola, Auli
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorMehtälä, Juha
dc.contributor.authorBahmanyar, Shahram
dc.contributor.authorMontgomery, Scott
dc.contributor.authorKorhonen, Pasi
dc.description.abstractBackground Our aim was to estimate and compare the prevalence of adverse pregnancy outcomes among pregnant women with multiple sclerosis (MS) exposed to interferon beta (IFNB) and among women with MS unexposed to any MS disease-modifying drug (MSDMD). Methods This cohort study used Finnish (1996–2014) and Swedish (2005–2014) national register data. Women with MS having IFNB dispensed 6 months before or during pregnancy as the only medication were considered as IFNB exposed (only IFNB-exposed), whereas women with MS unexposed to any MSDMD were considered unexposed (MSDMD-unexposed). Prevalence was described and compared using log-binomial or logistic regression and adjusted for potential confounders including maternal age and comorbidity. Results Among 2831 pregnancies, 2.2% of the only IFNB-exposed and 4.0% of the MSDMD-unexposed women had serious adverse pregnancy outcomes [elective termination of pregnancy due to foetal anomaly (TOPFA), major congenital anomaly (MCA) in live, or stillbirth]. After adjustments, the prevalence of serious adverse pregnancy outcomes was lower among the only IFNB-exposed compared with the MSDMD-unexposed [relative risk 0.55, 95% confidence interval (CI) 0.31–0.96]. The prevalence of individual outcomes, including MCA, spontaneous abortions, and stillbirths was not increased with IFNB exposure. Women with MS exposed to IFNB appeared more likely to terminate their pregnancy for reasons other than foetal anomaly, compared with MSDMD-unexposed pregnant MS patients (odds ratio 1.71, 95% CI 1.06–2.78). Conclusion In this large cohort study, no increase in the prevalence of adverse pregnancy outcomes was observed in women with MS exposed to IFNB compared with MS patients unexposed to any MSDMDs. This study together with other evidence led to a change in the labels of the IFNB products in September 2019 in the European Union, and IFNB use today may be considered during pregnancy, if clinically needed.en_US
dc.publisherSAGE Publicationsen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.titlePregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Swedenen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright The Author(s), 2020en_US
dc.source.journalTherapeutic Advances in Neurological Disorders (TAND)en_US
dc.identifier.citationTherapeutic Advances in Neurological Disorders. 2020, 13, 1-15.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell 4.0 Internasjonal